Oncology Today with Dr Neil Love

Featuring a slide presentation from Dr Julia Rotow, including the following topics:
Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00)
Key findings from the Phase III HARMONi-6 study; ongoing Phase III HARMONi-3 study (5:12)
Key findings from the Phase III HARMONi-2 study; ongoing Phase III HARMONi-7 study (9:59)
Clinician insights about the potential role of ivonescimab in the front-line setting (12:02)
Impetus for investigating ivonescimab in the relapsed/refractory (R/R) EGFR-mutant setting (14:01)
Key findings from the Phase III HARMONi-A and HARMONi studies (16:07)
Clinician insights about the potential role of ivonescimab in the treatment of R/R EGFR-mutant NSCLC; other novel PD-1/PD-L1 x VEGF bispecific antibodies under investigation (20:30)

CME information and select publications

Featuring perspectives from Dr Catherine C Coombs, including the following topics:
Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00)
Role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy for relapsed/refractory (R/R) CLL (10:42)
Fixed-duration venetoclax in combination with epcoritamab for R/R CLL/SLL; management of Richter’s transformation (15:50)
Novel Bruton tyrosine kinase degraders bexobrutideg (NX-5948) and tacabrutideg (BGB-16673) (22:51)

CME information and select publications

Featuring perspectives from Dr Catherine C Coombs, including the following topics:
Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)
Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)
Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05)
Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)

CME information and select publications

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:
Case: A woman in her mid 50s with BRCA1-mutated recurrent ovarian cancer receives mirvetuximab soravtansine — Ursula Matulonis, MD (0:00)

CME information and select publications

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:
Case: A woman in her early 50s with a germline BRCA1 mutation and ovarian cancer experiences disease recurrence after completing olaparib/bevacizumab maintenance therapy — Professor Jonathan A Ledermann (0:00)

CME information and select publications